U.S. Study of Drug Makers Criticizes 'Excess Profits'
A Congressional study of the costs of pharmaceutical development in the United States said today that even using the industry's own numbers and allowing for a substantial profit, drug companies still make "excess profits" totaling more than $2 billion a year. The profits were excessive, the study said, in the sense that compared with other high-technology, high-risk industries that are also dependent on scientific research, like electronics, the returns in the drug business are higher by two to three percentage points a year. The study's data indicate that drug companies' average profits are in the range of 13 to 14 percent.